BGPT: Paper Review: Cell size modulates ferroptosis susceptibility

Explore by Goal

Quick Answer Copied

Core finding:

Across multiple human cell lines and size-manipulation strategies, larger cells are consistently less susceptible to system xc⁻–inhibition–driven ferroptosis (erastin2/Era2), aligned with higher GSH (per protein mass), higher ferritin (FTH1/FTL), and lower lipid-peroxidation propensity mediated partly by lower ACSL4 abundance.

Long Answer

Paper Review (visual-first): Cell size modulates ferroptosis susceptibility

Publication ID: 10.1101/2025.10.25.684524 (preprint content provided in the prompt).

1) Evidence snapshot (what changes with cell size?)

The plotted IC50 values are taken directly from the paper’s example comparison at 72 h for HMEC cells sorted into small vs large G1 bins.

Mechanistic route (as proposed by the authors)

Smaller cells: higher basal and Era2-induced membrane lipid peroxidation (BODIPY-C11 oxidation ratio), consistent with a lower ferroptosis threshold.
GSH and ferritin scale with size: GSH concentration increases “super-scaling” when normalized to protein mass, and ferritin subunits (FTH1/FTL) increase ~1.6–2-fold.
ACSL4 decreases with size, reducing PUFA incorporation into membranes: ACSL4 concentration declines with increasing size and ACSL4 knockout abolishes the size-dependence of basal lipid peroxidation and reduces (but does not fully remove) the size dependence of Era2 sensitivity.
Context dependence: larger cells can be more sensitive to RSL3 (GPX4 inhibition) during G1 arrest, implying pathway-specific size effects.

2) Conceptual network map (inputs → ferroptosis modules)

The arrows reflect the directionality explicitly argued in the paper: larger cells have higher GSH and ferritin, lower ACSL4, and lower membrane lipid peroxidation, consistent with decreased susceptibility to Era2/system xc⁻ inhibition; the paper also reports the opposite trend for RSL3 during G1 arrest.

3) Robustness check & skeptical critique (where confounding could hide)

What is strong

Multi-model convergence: the size-dependent Era2 effect is shown not only in HMEC cells sorted by FACS, but also in HT-1080 and RPE-1 contexts using both sorting and cell-cycle arrest manipulation.
Mechanistic readouts align with ferroptosis biology: BODIPY-C11 ratiometric oxidation is used as a membrane lipid peroxidation proxy; and the paper connects size to GSH and ferritin, which are central ferroptosis modulators in the broader literature.

Skeptical issues / likely blind spots

“Cell size” vs “cell state” disentangling: size is inferred via SSC-A (FACS) and modulated via palbociclib or CCND1 knockdown. The paper itself notes that cell-cycle stage affects ferroptosis susceptibility (e.g., non-arrested cells differ from arrested populations) and that longer arrest increases size but also changes cellular physiology.
SSC-A as a proxy: SSC-A correlates with size but is not a direct geometric volume measure and can reflect internal complexity and granularity. The paper relies on established correlation arguments, but residual measurement bias could remain.
Incomplete proteomic coverage: the paper reports inability to detect SLC7A11 peptides and limited GCLC peptide counts in its proteomics reanalysis, leaving parts of the GSH supply chain partially unresolved relative to the authors’ proposed mechanism.
Mechanism is strong for Era2/system xc⁻ but may not generalize to all ferroptosis inducers: the paper’s contrast (Era2 vs RSL3) suggests non-uniform size mechanisms. That is conceptually expected, but it means “cell size → ferroptosis susceptibility” is not a single monotone rule across all ferroptosis triggers.

4) How convincing is the ACSL4-mediated link?

Evidence chain (as written)

Observation: ACSL4 concentration decreases with increasing cell size, while a control protein (β-actin) is constant.
Causality (lipid peroxidation module): in ACSL4 KO HT-1080 cells, the size dependence of basal membrane lipid peroxidation is abolished.
Partial causality (cell death phenotypes): ACSL4 KO reduces but does not eliminate the size dependence of Era2 sensitivity, consistent with ferroptosis being driven by multiple parallel processes (lipid incorporation vs iron-dependent peroxidation).

Independent support: ACSL4 is a known determinant of ferroptosis sensitivity via shaping lipid composition (PUFA enrichment).

5) Figures to compare mentally (from the provided text)

Key paper figures referenced in the excerpt

Fig. 1: high-throughput microscopy quantifies dose–response and kinetics across multiple death modalities; Era2 shows strongest size dependence.
Fig. 3: membrane lipid peroxidation (BODIPY-C11) anti-correlates with size in DMSO and is lower in larger cells among live cells during Era2 treatment.
Fig. 4: GSH abundance and scaling enzyme proteins increase with size; MCB/CFSE gives elevated GSH concentration in larger cells.
Fig. 5: ACSL4 decreases with size; ACSL4 knockout abolishes size dependence of basal lipid peroxidation; ACSL4 disruption reduces size dependence of Era2 ferroptosis.
Fig. 6: integrated model figure summarizes Era2 resistance via lower lipid peroxidation and higher glutathione in larger cells.

What would disprove or change the main conclusion?

If “size” is not causal (i.e., if the ferroptosis phenotype tracks more tightly with cell-cycle state markers or stress responses than with biophysical size), then the ACSL4/GSH explanations could be correlated but not mechanistic. The authors do partially address cell-cycle confounding with G1 gating/synchronization, but SSC-A and palbociclib effects remain conceptual vulnerabilities.
If ACSL4 is not sufficient/necessary under alternative ferroptosis triggers, then the authors’ mechanistic mapping would be incomplete. The RSL3 vs Era2 contrast suggests this is already partially the case, and further mapping across other ferroptosis inducers would strengthen (or refine) the generality.
If GSH/ferritin changes are downstream rather than upstream modulators, then perturbing these nodes would be required to prove directionality. The paper shows correlational enzyme/protein changes and uses ACSL4 knockout to affect lipid peroxidation and ferroptosis size dependence, which supports some causality, but GSH biosynthesis nodes are not genetically tested in the excerpt provided.

Actionable next queries (BGPT)

Bespoke author reviews

Feedback:

Updated: April 17, 2026